Clinical trial · no report yet · Phase 1/Phase 2
NCT03869190
Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)
- NCT03869190 ↗
- Terminated
- Hoffmann-La Roche
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 6 | |
| Podcasts | 2 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)
- Phase
- Phase 1/Phase 2
- Status
- Terminated
- Conditions
- Urothelial Carcinoma; Bladder Cancer
- Interventions
- Atezolizumab; Enfortumab Vedotin; Niraparib; Magrolimab (Hu5F9-G4); Tiragolumab; Sacituzumab Govitecan; Tocilizumab; Cisplatin; Gemcitabine
- Arms
- Atezolizumab for mUC Cohort (Stage 1) · Active comparator
- Atezolizumab + Enfortumab Vedotin for mUC Cohort (Stage 1) · Experimental
- Atezolizumab + Niraparib for mUC Cohort (Stage 1) · Experimental
- Atezolizumab + Magrolimab for mUC Cohort (Stage 1) · Experimental
- Atezolizumab + Tiragolumab for mUC Cohort (Stage 1) · Experimental
- Atezolizumab + Sacituzumab Govitecan for mUC Cohort (Stage 1) · Experimental
- Atezolizumab + Tocilizumab for mUC Cohort (Stage 1) · Experimental
- Atezolizumab + RO7122290 for mUC Cohort (Stage 1) · Experimental
- Atezolizumab + Enfortumab Vedotin for mUC Cohort (Stage 2) · Experimental
- Atezolizumab + Sacituzumab Govitecan for mUC Cohort (Stage 2) · Experimental
- Atezolizumab for Cisplatin-ineligible MIBC Cohort 1 PD-L1+ Arm 1 · Active comparator
- Atezolizumab + Tiragolumab for Cisplatin-ineligible MIBC Cohort 1 PD-L1+ Arm 2 · Experimental
- Atezolizumab for Cisplatin-ineligible MIBC Cohort 2 PD-L1- Arm 1 · Active comparator
- Atezolizumab + Tiragolumab for Cisplatin-ineligible MIBC Cohort 2 PD-L1- Arm 2 · Experimental
- Cisplatin-eligible MIBC Cohort 3 Arm 1 · Active comparator
- Cisplatin-eligible MIBC Cohort 3 Arm 2 · Experimental
- Enrollment
- 272
- Primary outcomes
- Stage 1 mUC Cohorts: Objective Response Rate (ORR)
- MIBC Cohorts: Pathological Complete Response (pCR)
- Sponsor
- Hoffmann-La Roche with Gilead Sciences, Inc., GlaxoSmithKline plc, Seattle Genetics and Astellas
- Start
- Jun 1, 2019
- Primary completion
- Oct 8, 2025
- Results posted
- Yes
- Registry record
- NCT03869190 · updated Aug 3, 2026
Publications
linked from the registry- Drakaki A, Powles T, Bamias A, Martin-Liberal J, Shin SJ, Friedlander T, Tosi D, Park C, Gomez-Roca C, Joly Lobbedez F, Castellano D, Morales-Barrera R, Moreno-Candilejo I, Flechon A, Yuen K, Rishipathak D, DuPree K, Young F, Michielin F, Shemesh CS, Steinberg EE, Williams P, Lee JL. Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma). Clin Cancer Res. 2023 Nov 1;29(21):4373-4384. doi: 10.1158/1078-0432.CCR-23-0798. PubMed 37651261